These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Kantrowitz JT; Javitt DC; Freedman R; Sehatpour P; Kegeles LS; Carlson M; Sobeih T; Wall MM; Choo TH; Vail B; Grinband J; Lieberman JA Neuropsychopharmacology; 2020 Jul; 45(8):1339-1345. PubMed ID: 32015461 [TBL] [Abstract][Full Text] [Related]
28. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435 [TBL] [Abstract][Full Text] [Related]
29. Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia. Minzenberg MJ; Yoon JH; Cheng Y; Carter CS Neuropsychopharmacology; 2016 Apr; 41(5):1231-40. PubMed ID: 26329382 [TBL] [Abstract][Full Text] [Related]
30. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Ma TM; Abazyan S; Abazyan B; Nomura J; Yang C; Seshadri S; Sawa A; Snyder SH; Pletnikov MV Mol Psychiatry; 2013 May; 18(5):557-67. PubMed ID: 22801410 [TBL] [Abstract][Full Text] [Related]
31. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. D'Souza DC; Radhakrishnan R; Perry E; Bhakta S; Singh NM; Yadav R; Abi-Saab D; Pittman B; Chaturvedi SK; Sharma MP; Bell M; Andrade C Neuropsychopharmacology; 2013 Feb; 38(3):492-503. PubMed ID: 23093223 [TBL] [Abstract][Full Text] [Related]
32. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899 [TBL] [Abstract][Full Text] [Related]
33. Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. McClure MM; Graff F; Triebwasser J; Perez-Rodriguez M; Rosell DR; Koenigsberg H; Hazlett EA; Siever LJ; Harvey PD; New AS Am J Psychiatry; 2019 Apr; 176(4):307-314. PubMed ID: 30654644 [TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Surti TS; Ranganathan M; Johannesen JK; Gueorguieva R; Deaso E; Kenney JG; Krystal JH; D'Souza DC Schizophr Res; 2023 Jun; 256():36-43. PubMed ID: 37141764 [TBL] [Abstract][Full Text] [Related]
35. Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial. Kruiper C; Sommer IEC; Koster M; Bakker PR; Durston S; Oranje B Schizophr Res; 2023 May; 255():148-154. PubMed ID: 36989672 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of Goh KK; Wu TH; Chen CH; Lu ML J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959 [TBL] [Abstract][Full Text] [Related]
37. Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. Fisher M; Loewy R; Carter C; Lee A; Ragland JD; Niendam T; Schlosser D; Pham L; Miskovich T; Vinogradov S Schizophr Bull; 2015 Jan; 41(1):250-8. PubMed ID: 24444862 [TBL] [Abstract][Full Text] [Related]
38. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial. Correll CU; Potkin SG; Zhong Y; Harsányi J; Szatmári B; Earley W J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30695290 [TBL] [Abstract][Full Text] [Related]
39. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468 [TBL] [Abstract][Full Text] [Related]
40. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]